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Abstract 
Synthesis of Fmoc-protected Nδ-acetyl-Nδ-(tert-butoxy)-L-ornithine has revealed it to be a 
metal-chelating amino-acid precursor. This protected amino acid was compatible with the 
preparation of ferrichrome peptides by standard Fmoc-based solid-phase peptide synthesis. 
Evaluation of deferriferrichrysin for metal ion chelation revealed that zirconium(IV) and 
titanium(IV) formed complexes with deferriferrichrysin. 
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1. Introduction 
Siderophores are iron(III)-chelating compounds produced by microorganisms such as bacteria and 
fungi that uptake iron ions under iron-deficient conditions.1 Siderophores contain three bidentate 
functional groups (hydroxamate, catecholate, α-hydroxycarboxylate) which form an extremely stable 
hexadentate, octahedral complex with iron(III). The hydroxamate-type siderophore 
deferriferrichrysin (1) is a cyclic hexapeptide produced by Aspergillus oryzae (Fig. 1).2 
Deferriferrichrome (2) and deferriferricrocin (3) also belong to the hydroxamate family of 
siderophores, and are produced from Ustilago sphaerogena3 and Aspergillus fumigatus,4 respectively. 
All cyclic hexapeptides contain three consecutive Nδ-acetyl-Nδ-hydroxy-L-ornithines (Aho), which 
are produced from L-ornithine in a biosynthetic process by L-ornithine-Nδ-oxygenase [e.g., Ustilago 
maydis sid1 protein (Sid1)5 and Aspergillus nidulans sidA protein (SidA)6] and Nδ-transacetylase7. 
Hydroxamic acid has metal-chelating functional groups that enable it to form complexes with 
various metals.8 For example, deferriferrichrysin also forms chelate complexes with aluminum(III),9 
gallium(III)10 and chromium(III).11 A 89Zr complex of the hydroxamate-type siderophore 
desferrioxamine B (4) has been applied to immuno-positron emission tomography (PET) in which 
the 89Zr complex is conjugated to monoclonal antibodies (mAbs) for visualization of small tumors.12 
Deferriferricrocin (3) and desferritriacetylfusarinine C (5) are the predominant siderophores 
produced by Aspergillus fumigatus.13 68Ga peptides of 3 and 5 have been investigated for PET-based 
diagnoses of invasive pulmonary aspergillosis (IPA).14 These siderophore–metal chelate complexes 
can provide therapeutic and diagnostic agents, so identification of novel metal complexes of 
deferriferrichrysin derivatives would be of great interest. 
There are two reports of the chemical synthesis of ferrichrome peptides containing three Aho 
residues. The first chemical synthesis of deferriferrichrome (2) was accomplished using 
L-δ-nitronorvaline by Keller-Schierlein and Maurer in 1969.15,16 In that process, the linear 
hexapeptide tert-butoxycarbonylglycyl-tris(L-δ-nitronorvalyl)-glycyl-glycine methyl ester 7 was 
prepared using the mixed anhydride method. After cyclization of linear peptide 7, reduction of the 
side-chain nitro group to a hydroxylamine group and subsequent acetylation produced 
deferriferrichrome (2) (Scheme 1). Kurita et al. also reported the total synthesis of ferrichrome using 
Nδ-tosyl-Nδ-benzyloxy-L-ornithine in 1974.17 A linear hexapeptide, 
tert-butoxycarbonylglycyl-tris(Nδ-tosyl-Nδ-benzyloxy-L-ornithyl)-glycyl-glycine methyl ester 8, was 
prepared using N,N'-dicyclohexylcarbodiimide (DCC) and N-hydroxysuccinimide (HOSu). After 
cyclization, removal of the tosyl group and acetylation of the protected cyclic hexapeptide 11 
followed by hydrogenation afforded deferriferrichrome (2) (Scheme 1). However, these approaches 
are not applicable to the facile structure–activity relationship (SAR) studies of deferriferrichrysin 
derivatives because the liquid-phase syntheses were not particularly versatile. 
In the present study, we investigated the synthesis of fully protected 
Nδ-acetyl-Nδ-hydroxy-L-ornithine, which can be utilized for the preparation of ferrichrome 
derivatives by Fmoc-based solid-phase peptide synthesis (SPPS). Additionally, formation of novel 
metal complexes of deferriferrichrysin was evaluated using the resulting cyclic peptides. 
 
2. Results and discussion 
2.1. Synthesis of fully protected Nδ-acetyl-Nδ-hydroxy-L-ornithine 
Nα-Fmoc-protected Nδ-acetyl-Nδ-hydroxy-L-ornithine derivative 20 was designed as a ‘building 
block’ for Fmoc-based SPPS (Scheme 2). We expected that a side-chain C3 unit with a terminal 
functional group of ornithine could be constructed by manipulations of derivatives of glutamic acid. 
Initially, the carboxylic acid in the commercially available Cbz-Glu(t-Bu)-OH 14 was protected with 
a benzyl group to afford an ester 15. After removal of the side-chain t-Bu group of 15, the resulting 
carboxylic acid was converted to an alcohol 16 by in situ preparation of a mixed anhydride followed 
by NaBH4-mediated reduction. Treatment of 16 with NsNH(Ot-Bu)18,19 under the Mitsunobu 
condition gave a protected hydroxylamine 17. The hydroxylamine 17 was converted to a protected 
hydroxamate 19 by removal of the Ns group and acetylation. Hydrogenation of 19 followed by 
Nα-Fmoc protection provided the desired product 20. This synthetic scheme was applied to the 
large-scale synthesis of 20, in which 12 g of the key building block 20 was obtained from 30 g of the 
starting material 14 (29% in eight steps). 
 
2.2. Preparation of ferrichrome peptides by Fmoc-based SPPS 
Using the resulting amino acid 20, peptide resin 22 was prepared on a 2-chlorotrityl [(2-Cl)Trt] 
resin 21 using standard Fmoc-based SPPS (Scheme 3). The consecutive couplings of three protected 
Aho 20 using N,N'-diisopropylcarbodiimide (DIC)/HOBt proceeded smoothly as the standard amino 
acids. After treatment of the resin with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), a protected linear 
peptide 23 was cyclized using diphenylphosphoryl azide (DPPA)/NaHCO320,21 to give a cyclic 
peptide 24. Removal of the side chain-protecting groups in 24 provided deferriferrichrysin (1). The 
overall yield from resin loading was 8%. 
To demonstrate the potential utility of the established protocol, deferriferrichrome (2) and 
deferriferricrocin (3) were also synthesized. These two compounds were obtained efficiently by 
merely altering the coupling components in SPPS. Spectral data showed good agreement with the 
reported spectra.4,22,23 
 
2.3. Metal-chelating properties of deferriferrichrysin 
Formation of the complex of deferriferrichrysin with various metals was investigated. We chose 
strontium(II) [Sr(II)], yttrium(III) [Y(III)], indium(III) [In(III)], gadolinium(III) [Gd(III)], rhenium(I) 
[Re(I)], rhenium(V) [Re(V)] and zirconium(IV) [Zr(IV)]. These have been used for clinical 
diagnoses and treatments. Mixtures of a metal salt and deferriferrichrysin were analyzed by 
high-performance liquid chromatography (HPLC) and electrospray ionization-mass spectrometry 
(ESI-MS) (Table 1).24 
Formation of a metal–deferriferrichrysin complex in the mixture was not observed using Sr(II), 
Y(III), In(III), Gd(III) or Re(I) (entries 2–6). When using Re(V), a deferriferrichrysin peak 
disappeared and a new peak was observed (tR = 15.9 min; entry 7). ESI-MS analyses revealed that 
the product in the Re(V) mixture (m/z 700) was not the expected Re(V)–deferriferrichrysin complex 
(m/z 931). However, the reduced deferriferrichrysin analog was obtained, in which three 
hydroxamate groups were converted to amide groups (entry 7). Alcohols work as reducing agents for 
transition metals including rhenium,25 palladium26 and ruthenium,27 so Re(V) might be reduced by 
methanol to a reactive low-valent ion, which reduced deferriferrichrysin. When DMF was used as the 
solvent, fully reduced deferriferrichrysin was not observed.28 This observation supported our 
proposal. In the mixture of Zr(IV) solution, formation of the desired Zr(IV)–deferriferrichrysin 
complex was observed (tR = 15.5 min; m/z 834; entry 8), which was characterized by 
ultraviolet–visible (UV–vis) spectroscopy, circular dichroism (CD) spectroscopy, nuclear magnetic 
resonance (NMR) spectroscopy, and fast atom bombardment-high resolution mass spectrometry 
(FAB-HRMS). The physiochemical properties of this complex are being investigated.29 
Furthermore, we examined the formation of the titanium(IV) [Ti(IV)]–deferriferrichrysin complex 
because Ti and Zr are group-4 elements. When a mixture of Ti(IV) and deferriferrichrysin was 
analyzed by HPLC, two new peaks with an identical molecular weight of the 
Ti(IV)–deferriferrichrysin complex (m/z 792) were obtained (tR = 18.0, 18.3 min; entry 9). Each 
product was interconverted to the other product. This finding suggested that the Ti(IV) complex may 
have existed as a mixture of two equilibrated structures.30 
 
3. Conclusions 
We established a facile synthetic protocol for a fully protected Aho derivative 20. Using this key 
component 20 for Fmoc-based SPPS, deferriferrichrysin and derivatives were synthesized. This 
facile synthetic protocol may be useful for the preparation of Aho-containing peptides to conduct 
SAR studies and structure–function relationship studies. We also identified two new metal-chelating 
complexes of deferriferrichrysin with Zr(IV) and Ti(IV). Some Zr(IV) and Ti(IV) complexes have 
been used as catalyst materials in chemical reactions such as olefin polymerization,31–33 
epoxidation,34,35 and aldol reaction.36,37 Hence, these new peptide–metal complexes could be novel 
reagents with unique reactivity. Further studies on the application of these deferriferrichrysin–metal 




4.1.1. General methods 
All moisture-sensitive reactions were performed using syringe-septum cap techniques under an 
argon atmosphere and all glassware was dried in an oven at 80 °C for 2 h prior to use. Melting points 
were measured by a hot stage melting point apparatus and are uncorrected. Optical rotations were 
measured with a JASCO P-1020 polarimeter. For flash chromatography, Wakosil C-300E was 
employed. For analytical HPLC, a COSMOSIL 5C18-ARII column (4.6 × 250 mm, Nacalai Tesque 
Inc., Kyoto, Japan) was employed with a linear gradient of MeCN containing 0.1 % (v/v) TFA at a 
flow rate of 1 mL/min on Shimadzu LC-20ADvp (Shimadzu corporation, Ltd, Kyoto, Japan). 
Preparative HPLC was performed using a COSMOSIL 5C18-ARII column (20 × 250 mm, Nacalai 
Tesque Inc.) with a linear gradient of MeCN containing 0.1 % (v/v) TFA at a flow rate of 8 mL/min 
on Shimadzu LC-6AD (Shimadzu corporation, Ltd). 1H NMR spectra were recorded using a JEOL 
ECA-500 spectrometer, and chemical shifts are reported in δ (ppm) relative to TMS (in CDCl3), 
DMSO (in DMSO-d6) or H2O (in D2O) as an internal standard. 13C NMR spectra were recorded 
using a JEOL ECA-500 spectrometer and referenced to the residual CHCl3 (in CDCl3), DMSO (in 
DMSO-d6), or MeOH or dioxane (in D2O) signal. Chemical shifts were reported in parts per million 
with the residual solvent peak used as an internal standard. 1H NMR spectra are tabulated as follows: 
chemical shift, multiplicity (br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), 
number of protons, and coupling constant(s). Exact mass (HRMS) spectra were recorded on a 
JMS-HX/HX 110A mass spectrometer. Infrared (IR) spectra were obtained on a JASCO FT/IR-4100 
FT-IR spectrometer with JASCO ATR PRO410-S. UV–vis and CD spectra were recorded on 
Shimadzu UV-2450 UV–vis spectrophotometer and JASCO J-720 circular dichroism spectrometer. 
The preparation and characterization of compounds 15,38 and 1639 were reported previously. 
 
4.1.2. Benzyl (S)-2-[N-(benzyloxycarbonyl)amino]-5-[N-(tert-butoxy)-N-(2-nitrophenyl- 
sulfonyl)amino]pentanoate (17) 
To a solution of the alcohol 1639 (50.3 mg, 0.14 mmol), PPh3 (75.4 mg, 0.29 mmol) and 
NsNH(Ot-Bu) (78.0 mg, 0.28 mmol) in THF (1.4 mL) was added DEAD in toluene (2.2 M, 0.13 mL, 
0.28 mmol) at 0 °C under argon, and the mixture was stirred at room temperature for 2 h. 
Concentration under reduced pressure followed by flash chromatography over silica gel with 
n-hexane–EtOAc (2:1) gave the crude title compound 17 (91.2 mg), which was used in the next step 
without further purification. 
Compound 17 (purified for characterization): [α]26D +6.17 (c 1.02, CHCl3); IR (neat): 1725 (C=O); 
1H NMR (500 MHz, CDCl3) δ 1.27 (s, 9H), 1.56–1.66 (m, 1H), 1.66–1.79 (m, 2H), 1.83–1.93 (m, 
1H), 3.02–3.16 (m, 1H), 3.31–3.43 (m, 1H), 4.30–4.44 (m, 1H), 5.05–5.20 (m, 4H), 5.27 (d, J = 8.0 
Hz, 1H), 7.28–7.39 (m, 10H), 7.46 (d, J = 5.7 Hz, 1H), 7.60–7.75 (m, 2H), 8.00–8.06 (m, 1H); 13C 
NMR (125 MHz, CDCl3) δ 22.9, 27.7 (3C), 29.8, 53.6, 55.2 67.0, 67.3, 84.0, 123.4, 127.1, 128.1 
(2C), 128.2, 128.3 (2C), 128.49, 128.54 (2C), 128.6 (2C), 130.8, 132.9, 134.5, 135.1, 136.2, 149.4, 
155.8, 171.8; HRMS (FAB), m/z calcd for C30H36N3O9S (MH+) 614.2167, found: 614.2166. 
 
4.1.3. Benzyl (S)-2-[N-(benzyloxycarbonyl)amino]-5-[N-(tert-butoxy)amino]pentanoate (18) 
To a stirred solution of crude ester 17 (91.2 mg) in DMF (1.5 mL) were added thiophenol (28.8 
μL, 0.28 mmol) and K2CO3 (60.2 mg, 0.42 mmol) at room temperature, and the mixture was stirred 
at the same temperature for 5 h. After concentration under reduced pressure, the residue was 
extracted with EtOAc, and washed with saturated NH4Cl, brine, saturated NaHCO3 and brine, and 
dried over MgSO4. Concentration under reduced pressure followed by flash chromatography over 
silica gel with n-hexane–EtOAc (3:1) gave the title compound 18 (50.8 mg, 0.12 mmol, 84% from 
16) as a colorless oil: [α]27D –1.14 (c 1.13, CHCl3); IR (neat): 1725 (C=O); 1H NMR (500 MHz, 
CDCl3) δ 1.13 (s, 9H), 1.41–1.53 (m, 2H), 1.68–1.78 (m, 1H), 1.85–1.95 (m, 1H), 2.81 (t, J = 6.9 Hz, 
2H), 4.40–4.47 (m, 1H), 5.10 (s, 2H), 5.11–5.22 (m, 2H), 5.47 (d, J = 8.0 Hz, 1H), 7.27–7.39 (m, 
10H); 13C NMR (125 MHz, CDCl3) δ 23.1, 26.7 (3C), 30.5, 52.1, 53.8, 66.9, 67.1, 76.7, 128.07 (2C), 
128.12, 128.2 (2C), 128.4, 128.5 (2C), 128.6 (2C), 135.3, 136.2, 155.9, 172.2; HRMS (FAB), m/z 
calcd for C24H33N2O5 (MH+) 429.2384, found: 429.2384. 
 
4.1.4. Benzyl (S)-5-[N-acetyl-N-(tert-butoxy)amino]-2-[N-(benzyloxycarbonyl)amino]penta- 
noate (19) 
To a solution of ester 18 (97.2 mg, 0.23 mmol) in CH2Cl2 (4.5 mL) were added pyridine (36.5 μL, 
0.45 mmol), 4-(dimethylamino)pyridine (DMAP, 14.1 mg, 0.12 mmol) and Ac2O (32.1 μL, 0.34 
mmol) at room temperature. After stirring for 1 h, pyridine (36.5 μL, 0.45 mmol) and Ac2O (32.1 μL, 
0.34 mmol) were added to the mixture, and the resulting mixture was stirred overnight. After dilution 
with CH2Cl2, the mixture was washed with saturated NaHCO3 and brine, and dried over MgSO4. 
Concentration under reduced pressure followed by flash chromatography over silica gel with 
n-hexane–AcOEt (1:1) gave the title compound 19 (101 mg, 0.22 mmol, 95%) as a colorless oil: 
[α]22D +1.01 (c 1.03, CHCl3); IR (neat): 1721 (C=O), 1654 (C=O); 1H NMR (500 MHz, DMSO-d6, 
100 °C) δ 1.24 (s, 9H), 1.60–1.75 (m, 4H), 1.99 (m, 3H), 3.52–3.59 (m, 2H), 4.11–4.17 (m, 1H), 5.05 
(s, 2H), 5.09–5.16 (m, 2H), 7.27–7.39 (m, 11H); 13C NMR (125 MHz, DMSO-d6, 100 °C) δ 20.5, 
22.2, 26.9 (3C), 27.9, 48.7, 53.5, 65.1, 65.4, 81.6, 127.05 (2C), 127.12 (2C), 127.36, 127.42, 128.8 




pentanoic acid (20) 
The ester 19 (101.7 mg, 0.22 mmol) was treated with 10% Pd/C (43.3 mg) in MeOH (1.2 mL) 
under H2 atmosphere at room temperature for 3.5 h. After filtration and concentration under reduced 
pressure, the residue was dissolved in MeCN (1.4 mL) and water (1.4 mL). (i-Pr)2NEt (75.3 μL, 0.43 
mmol) and Fmoc-OSu (148 mg, 0.43 mmol) were added at room temperature, and the mixture was 
stirred overnight at the same temperature. The reaction was quenched by addition of 1 M HCl. After 
concentration under reduced pressure, the residue was extracted with EtOAc. The extract was 
washed with 1 N HCl and brine, and dried over MgSO4. Concentration under reduced pressure 
followed by flash chromatography over silica gel with EtOAc containing 0.5% AcOH gave the title 
compound 20 (104 mg, 0.22 mmol, quant.) as white amorphous solid: [α]22D –5.4 (c 1.09, DMSO); 
IR (neat): 3373 (NH), 1718 (C=O), 1650 (C=O); 1H NMR (500 MHz, DMSO-d6, 100 °C) δ 1.26 (s, 
9H), 1.56–1.74 (m, 4H), 2.02 (s, 3H), 3.53–3.61 (m, 2H), 3.96–4.02 (m, 1H), 4.20–4.24 (m, 1H), 
4.28–4.32 (m, 2H), 7.12–7.20 (m, 1H), 7.29–7.34 (m, 2H), 7.38–7.43 (m, 2H), 7.67–7.72 (m, 2H), 
7.85 (d, J = 6.9 Hz, 2H); 13C NMR (125 MHz, DMSO-d6, 100 °C) δ 20.6, 22.4, 26.8 (3C), 28.1, 46.4, 
48.9, 53.2, 65.4, 81.6, 119.4 (2C), 124.6 (2C), 126.4 (2C), 126.9 (2C), 140.3 (2C), 143.5 (2C), 155.4, 
172.7, 173.6; HRMS (FAB), m/z calcd for C26H33N2O6 (MH+) 469.2333, found: 469.2335. 
 
4.1.6. Peptide synthesis 
The protected linear peptide 23 was constructed by Fmoc-based solid-phase synthesis on 
H-Gly-(2-Cl)Trt resin (0.80 mmol/g, 125 mg, 0.10 mmol). t-Bu group for Ser was employed for 
side-chain protection. Fmoc-Ser(t-Bu)-OH (0.50 mmol) and Fmoc-protected ornithine derivative 20 
(0.30 mmol) were coupled by using DIC (46.4 μL, 0.3 mmol/77.4 μL, 0.5 mmol) and HOBt·H2O 
(45.9 mg, 0.3 mmol/76.6 mg, 0.5 mmol) in DMF. Completion of each coupling reaction was 
ascertained using the Kaiser ninhydrin test. The Fmoc-protecting group was removed by treating the 
resin with 20% piperidine in DMF. The resulting protected peptide resin 22 was subjected to 
HFIP–CH2Cl2 (2:8, 25 mL) treatment at room temperature for 2 h. After filtration of the residual 
resin, the filtrate was concentrated under reduced pressure to give a crude linear peptide 23. 
By use of a procedure identical with that described for the preparation of 23, the protected linear 
peptides for deferriferrichrome (2) and deferriferricrocin (3) were obtained. 
 4.1.7. Deferriferrichrysin (1) 
To a mixture of the resulting linear peptide 23 (55.6 mg) and NaHCO3 (42.0 mg, 0.500 mmol) in 
DMF (40 mL) was added DPPA (53.9 μL, 0.250 mmol) at –40 °C. The mixture was stirred for 48 h 
with warming to room temperature and then filtered. The filtrate was concentrated under reduced 
pressure, followed by flash chromatography over silica gel with CHCl3–MeOH (9:1) to give the 
crude protected cyclic peptide 24. The crude peptide 24 was treated with 95% TFA (2 mL) at room 
temperature for 6 h. The mixture was poured into ice-cold dry Et2O (10 mL). The resulting powder 
was collected by centrifugation and the washed three times with ice-cold dry Et2O. The crude 
product was purified by preparative HPLC to afford the deferriferrichrysin 1 (6.1 mg, 0.0082 mmol, 
8.2% yield based on H-Gly-(2-Cl)Trt resin) as yellow freeze-dried powder: [α]31D –16.8 (c 1.03, 
H2O); 1H NMR (500 MHz, D2O) δ 1.63–2.03 (m, 12H), 2.12–2.19 (m, 9H), 3.60–3.75 (m, 6H), 
3.85–3.98 (m, 5H), 4.08 (d, J = 16.6 Hz, 1H), 4.29–4.35 (m, 1H), 4.36–4.48 (m, 4H); 13C NMR (125 
MHz, D2O, internal standard; dioxane) δ –47.3 (3C), –44.2, –44.1, –43.9, –38.8, –38.63, –38.61, 
–23.5, –19.4 (2C), –19.3, –13.0, –12.4 (2C), –10.6, –10.5, –6.1, –6.0, 104.7, 105.1, 105.4, 106.9, 
107.1, 107.3 (4C); HRMS (FAB), m/z calcd for C29H50N9O14 (MH+) 748.3472, found: 748.3479. The 
NMR data was in good agreement with the literature data.4,22 
 
4.1.8. Deferriferrichrome (2) 
By use of a procedure identical with that described for the preparation of the deferriferrichrysin 1, 
the deferriferrichrome 2 (4.9 mg, 0.0071 mmol, 7.1% based on H-Gly-(2-Cl)Trt resin) was obtained 
as yellow freeze-dried powder: [α]27D –2.6 (c 0.351, H2O); 1H NMR (500 MHz, D2O) δ 1.63–2.02 (m, 
12H), 2.12–2.19 (m, 9H), 3.61–3.78 (m, 6H), 3.91 (d, J = 16.6 Hz, 1H), 3.95–4.11 (m, 4H), 4.15 (d, J 
= 17.2 Hz, 1H), 4.30–4.39 (m, 1H), 4.39–4.49 (m, 2H); 13C NMR (125 MHz, D2O, internal standard; 
dioxane) δ –47.30, –47.27 (2C), –44.5, –44.2, –44.0, –39.2, –38.4, –37.9, –24.0, –23.9, –23.6, –19.4 
(2C), –19.3, –12.8, –12.7, –12.6, 105.0, 105.4, 105.6, 107.2, 107.3 (2C), 107.4, 107.48, 107.55; 
HRMS (FAB), m/z calcd for C27H46N9O12 (MH+) 688.3260, found: 688.3256. The NMR data was in 
good agreement with the literature data.4,22 
 
4.1.9. Deferriferricrocin (3) 
By use of a procedure identical with that described for the preparation of the deferriferrichrysin 1, 
the deferriferricrocin 3 (16.0 mg, 0.0223 mmol, 22% based on H-Gly-(2-Cl)Trt resin) was obtained 
as yellow freeze-dried powder: [α]30D –16.0 (c 1.14, H2O); 1H NMR (500 MHz, D2O) δ 1.63–1.96 (m, 
12H), 2.16 (s, 9H), 3.60–3.75 (m, 6H), 3.85 (d, J = 16.6 Hz, 1H), 3.90 (dd, J = 11.5, 5.2 Hz, 1H), 
3.95 (dd, J = 11.5, 5.7 Hz, 1H), 3.98–4.09 (m, 2H), 4.16 (d, J = 16.6 Hz, 1H), 4.27–4.33 (m, 1H), 
4.35–4.45 (m, 2H), 4.50–4.55 (m, 1H); 13C NMR (125 MHz, D2O, internal standard; dioxane) δ 
–47.3 (3C), –44.4, –44.2 (2C), –39.2, –38.3, –38.0, –23.9, –23.7, –19.4 (2C), –19.3, –12.8, –12.7, 
–12.6, –11.4, –6.2, 104.7, 105.0, 105.4, 106.8, 107.2, 107.27 (3C), 107.34; HRMS (FAB), m/z calcd 
for C28H48N9O13 (MH+) 718.3366, found: 718.3371. The NMR data was in good agreement with the 
literature data.22,23 
 
4.1.10. Zirconium(IV)–deferriferrichrysin complex (S1) 
To a solution of deferriferrichrysin (14.4 mg, 0.0193 mmol) in H2O (1 mL) was added a solution 
of ZrCl4 (17.4 mg, 0.0747 mmol) in H2O (1 mL) at room temperature. The mixture was purified by 
preparative HPLC to afford the titled compound S1 (8.9 mg, 0.0106 mmol, 55% yield) as colorless 
freeze-dried powder: [α]29D +89.4 (c 0.926, DMSO); 1H NMR (500 MHz, D2O) δ 1.34–1.46 (m, 1H), 
1.50–1.59 (m, 1H), 1.65–1.80 (m, 4H), 1.82–1.89 (m, 1H), 1.92–2.11 (m, 13H), 2.22–2.36 (m, 1H), 
3.36–3.51 (m, 2H), 3.51–3.63 (m, 1H), 3.67–3.77 (m, 2H), 3.77–3.93 (m, 5H), 4.02–4.12 (m, 1H), 
4.12–4.19 (m, 2H), 4.22–4.27 (m, 1H), 4.36 (t, J = 3.4 Hz, 1H), 4.48 (dd, J = 13.2, 2.9 Hz, 1H), 
4.83–4.89 (m, 1H), 6.86–6.93 (m, 1H), 8.51–8.58 (m, 1H), 9.00–9.05 (m, 1H); 13C NMR (125 MHz, 
D2O, internal standard; MeOH) δ 17.3, 17.5, 17.9, 22.9, 26.0, 26.4, 27.0, 27.2, 29.5, 44.1, 50.5, 50.8, 
51.8, 54.1, 55.9, 56.0, 59.2, 59.9, 61.45, 61.49, 165.5, 166.1, 166.2, 171.7, 171.9, 173.2, 173.7, 174.9, 
177.8; HRMS (FAB), m/z calcd for C29H46N9O14Zr (M+) 834.2206, found: 834.2202. 
 
4.2. Metal-chelating experiment 
To a 100 μL solution of deferriferrichrysin in solvent (1.0 mM) was added a 100 μL solution of 
metal salts in solvent (5.0 mM) at room temperature. Sr(NO3)2, Y standard solution [Y(NO3)3 in 1 
mol/L HNO3], InCl3, Gd(NO3)3, ZrCl4 and 30% Ti(SO4)2 solution were dissolved in H2O; Re(CO)5Cl 
and ReCl5 were dissolved in DMF and methanol, respectively. After 24 h, the mixture was analyzed 
by HPLC and assessment of ESI-MS spectra. HPLC conditions: a linear gradient of solvent B in 
solvent A (0–25% over 25 min); COSMOSIL 5C18-ARII column (4.6 × 250 mm); flow rate, 1 
mL/min; solvent A: 0.1% TFA–H2O; solvent B: 0.1% TFA–MeCN; detection at 220 nm. 
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Scheme 2. Synthesis of an Fmoc-protected hydroxamate building block for solid-phase peptide 
synthesis. Reagents and conditions: (a) BnOH, DCC, DMAP, CH2Cl2, rt, overnight (90%); (b) (i) 
TFA, CH2Cl2, rt, 2 h; (ii) EtOCOCl, Et3N, THF, –10 °C, 1 h, then NaBH4, H2O, rt, 5 h (81%); (c) 
NsNH(Ot-Bu), PPh3, DEAD, THF, rt, 2 h; (d) thiophenol, K2CO3, DMF, rt, 5 h (84% from 16); (e) 
Ac2O, pyridine, DMAP, CH2Cl2, rt, overnight (95%); (f) (i) H2, Pd/C, MeOH, rt, 2.5 h; (ii) FmocOSu, 










































Scheme 3. Synthesis of deferriferrichrysin. Reagents and conditions: (a) Fmoc-based SPPS; (b) HFIP, 
CH2Cl2, rt, 2 h; (c) DPPA, NaHCO3, DMF, –40 °C to rt, 61.5 h; (d) TFA, H2O, rt, 9 h (8% from 21); 
Aho = Nδ-acetyl-Nδ-hydroxy-L-ornithine. 
Table1. HPLC and ESI-MS analyses of deferriferrichrysin–metal complexes. 
Entry Metala tR (min)b m/z (ESI) 
1 none 18.7 748 [MH+] 
2 Sr(NO3)2 18.6 748 [MH+] 
3 Y(NO3)3c 18.9 748 [MH+] 
4 InCl3 18.6 748 [MH+] 
5 Gd(NO3)3 18.8 748 [MH+] 
6 Re(CO)5Cld 18.8 748 [MH+] 
7 ReCl5e 15.9 700 [(M–3O)H+] 






10 Fe(NO3)3g 20.1 801 [(M+Fe–3H)H+] 
aMetal salt was dissolved in H2O. bHPLC conditions: a linear gradient of solvent B in solvent A 
(0–25% over 25 min); COSMOSIL 5C18-ARII column (4.6 × 250 mm); flow rate, 1 mL/min; 
solvent A: 0.1% TFA–H2O; solvent B: 0.1% TFA–MeCN; detection at 220 nm. cYttrium standard 
solution [Y(NO3)3 in 1 mol/L HNO3] was used. dRe(CO)5Cl was dissolved in DMF. eReCl5 was 
dissolved in MeOH.  f30% Ti(SO4)2 solution was used. gIron standard solution [Fe(NO3)3 in 0.1 
mol/L HNO3] was used. 
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